New medical drugs for HIV and Parkinson's disease to arrive to Serbia

Source: Beta Thursday, 07.09.2017. 08:21
Comments
Podeli
Illustration (Photo: OSABEE/shutterstock.com)Illustration
The pharmaceutical company Actavis announced yesterday that it would provide the first generic substitute for HIV therapy to patients and the health system of Serbia, leading to considerable savings.

– This is a therapy equally as efficient as the existing one, except that now it will be available at a considerably lower price, which will enable a larger number a HIV patients to be treated using a modern combination of drugs – Actavis says in its press release.


It is added that Actavis would provide the first generic copy of a fixed combination of drugs for Parkinson's disease before the end of the year, reducing the participation cost paid by the patients.

– Thanks to the fact that we are a part of the Teva Group, one of the biggest pharmaceutical companies in the world, we are now able to provide Serbia with a large number of modern and proven medical drugs used in nearly all fields of therapy, under conditions which will enable the healthcare fund and the patients to use a part of the money for other purposes – said Pavle Marjanovic, General Manager of Actavis for Serbia and Montenegro.

He announced that Actavis would also provide four very important medicines for the therapy of hospital patients.

The Leskovac-based medical drug factory Zdravlje is a member of Actavis.
Comments
Your comment
Full information is available only to commercial users-subscribers and it is necessary to log in.

Forgot your password? Click here HERE

For free test use, click HERE

Pratite na našem portalu vesti, tendere, investicione projekte, grantove i pravnu regulativu.
Registracija na eKapiji vam omogućava pristup potpunim informacijama i dnevnom biltenu
Naš dnevni ekonomski bilten će stizati na vašu mejl adresu krajem svakog radnog dana. Bilteni su personalizovani prema interesovanjima svakog korisnika zasebno, uz konsultacije sa našim ekspertima.